Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
Authors not listed
Nordic Lymphoma Group · 2021
Abstract
This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL).
Acalabrutinib (ACP-196) is a next generation bruton tyrosine kinase (BTK) inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab.
In this trial proposal, we will also assess the activity of this combination in comparison to a historical control of ibrutinib + rituximab, consisting of the experimental arm of ibrutinib + rituximab in the randomized ENRICH trial (EudraCT number 2015-000832-13), and data from our previous trial with R-bendamustine-lenalidomide (NLG-MCL4).
The duration of treatment will be a minimum of 12 months. Patients in molecular remission in blood and bone marrow and in complete remission according to CT, will then stop acalabrutinib, but continue on rituximab for a maximum of 36 months. Patients that are minimal residual disease positive (MRD+) will be evaluated again every 6 months and continue on acalabrutinib for a maximum of 36 months.
Patients without a molecular marker, that cannot be followed with MRD, will stop treatment if in CR with PET at 12 months, and be followed by PET-CT every 6 months for a maximum of 36 months.
Patients who convert back to MRD positive after stopping acalabrutinib are reinstalled on acalabrutinib until progression.
Patients with TP53 aberrations and/or blastoid histology, will monitor MRD but continue with treatment until progression regardless of MRD results.
A planned interim analysis will be performed when 40 patients have undergone response assessment after 6 months, for futility and efficacy.
If less than 16 of 40 patients obtain a CR, the trial will be stopped due to futility.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
Anonymous. (2021). Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma. <em>Nordic Lymphoma Group</em>. https://clinicaltrials.gov/study/NCT05214183
Vancouver
Anonymous. Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma. Nordic Lymphoma Group. 2021.
BibTeX
@misc{anon2021Acalab,
title = {Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma},
author = {Anonymous},
journal = {Nordic Lymphoma Group},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
M.D. Anderson Cancer Center 2013
Open access · US-GOV
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL
Medical University of Vienna 2011
Open access · US-GOV
Long-term Follow-up of Subfoveal Neovascular AMD
Versailles Hospital 2007
Open access · US-GOV
An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Dasatinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL).
Institut Paoli-Calmettes 2024
Open access · US-GOV
REINFORCED PROPHYLAXIS OF GVH IN ELDERLY PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: USE OF A LOW DOSE OF POST-ALLOGRAFT ANTI-LYMPHOCYTIC SERUM
Hoffmann-La Roche 2010
Open access · US-GOV
Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES
Blood 2009
Open access · OA